Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics (NASDAQ: AVTX), a clinical stage biotech company focused on IL-1β-based treatments for immune-mediated inflammatory diseases, has announced its participation in three upcoming investor conferences in September 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Avalo Therapeutics (NASDAQ: AVTX), a clinical stage biotech company focused on IL-1β-based treatments for immune-mediated inflammatory diseases, has announced its participation in three upcoming investor conferences in September 2025.
The company will present at the Cantor Global Healthcare Conference (September 3), the H.C. Wainwright Global Investment Conference (September 9), and the Stifel Virtual Immunology and Inflammation Forum (September 15). All presentations will be available via webcast on the company's investor relations website, with replays accessible for at least 30 days.
Details
News Market Reaction – AVTX
On Aug 27, the day this news came out, AVTX closed 1.58% above the previous close.
Data tracked by StockTitan Argus for the Aug 27 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences:
Cantor Global Healthcare Conference
Fireside Chat
September 3, 2025, at 2:10 pm ET
H.C.Wainwright 27th Annual Global Investment Conference
Presentation
September 9, 2025, at 2:30 pm ET
Stifel 2025 Virtual Immunology and Inflammation Forum
Fireside Chat
September 15, 2025, at 11:00 am ET
Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.
About Avalo Therapeutics
Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead asset, AVTX-009, is in a Phase 2 clinical trial for hidradenitis suppurativa (HS). We’re also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. For more information about Avalo, please visit www.avalotx.com.
About AVTX-009
AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a pro-inflammatory cytokine that plays a central role in the pathogenesis of a wide range of human diseases.1 It activates immune cells that generate proinflammatory cytokines, including IL-6, TNF-α, and IL-17. Dysregulated IL-1β signaling is a major driver of inflammation, contributing to the progression of autoimmune disorders. IL-1β inhibition has proven effective in multiple immune mediated inflammatory diseases.1-3
References: 1Dinarello CA. Immunol Rev. 2018;281(1):8-27. 2Kany S et al. Int J Mol Sci. 2019;20(23):6008. 3Kimball AB et al. Presented at: American Academy of Dermatology; March 8-12, 2024; San Diego, CA.
For media and investor inquiries
Christopher Sullivan, CFO
Avalo Therapeutics, Inc.
ir@avalotx.com
410-803-6793
or
Meru Advisors
Lauren Glaser
lglaser@meruadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.